PALI
Palisade Bio, Inc.
$2.10
+1.94%
2026-08-21
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Key Fundamentals
P/E Ratio
3.29
Forward P/E
-7.64
EPS (TTM)
$0.65
ROE
-51.4%
Profit Margin
0.0%
Debt/Equity
0.06
Price/Book
3.05
Beta
1.54
Market Cap
$372.9M
Avg Volume (10D)
1.5M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$2.29
60D Low
$1.64
Avg Volume
2.9M
Latest Close
$2.10
Get breakout alerts for PALI
Sign up for Breakout Scanner to receive daily notifications when PALI triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Palisade Bio, Inc. (PALI) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PALI daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PALI operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.